Genetic Alterations in NSCLC: Prognostic Implications and Impact on Therapeutic Resistance.
1/5 보강
Worldwide, the incidence of lung cancer is projected to continue its upward trend, with an estimated 2.5 million new cases annually.
APA
Neelesh BT, Bhardwaj K, et al. (2025). Genetic Alterations in NSCLC: Prognostic Implications and Impact on Therapeutic Resistance.. American journal of clinical oncology. https://doi.org/10.1097/COC.0000000000001289
MLA
Neelesh BT, et al.. "Genetic Alterations in NSCLC: Prognostic Implications and Impact on Therapeutic Resistance.." American journal of clinical oncology, 2025.
PMID
41430544 ↗
Abstract 한글 요약
Worldwide, the incidence of lung cancer is projected to continue its upward trend, with an estimated 2.5 million new cases annually. Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for ~85% of all cases. One of the challenges associated with NSCLC management is incomplete understanding of the underlying molecular mechanisms. Tumors often harbor multiple genetic changes that interact in complex ways, influencing tumor behavior, including the growth rate, metastatic potential as well as response and resistance to therapies. Identification of genetic alterations is desirable to anticipate resistance mechanisms and guide the development of combination therapies to overcome them. It also allows better stratification of patients in clinical trials, ensuring that the therapies are tested in the most appropriate populations, improving the chances of identifying effective treatments and tailor treatment plans based on the specific genetic profile of a patient's tumor. This review summarizes the established genetic and epigenetic alterations associated with NSCLC and discusses the need for understanding the molecular pathogenesis.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Role of Cytokines in Oligometastatic Non-Small-Cell Lung Cancer Treated with Stereotactic Radiation Therapy: An Observational Pilot Study.
- Development and validation of a novel nomogram model for predicting postoperative survival of T4N0M0 NSCLC: a population-based survival analysis.
- Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
- RBM15 Mediated m6A Modification of SRSF1 Inhibits Cuproptosis in Non-Small Cell Lung Cancer by Mediating ATP7B Alternative Splicing.
- Updates on Clinical Trials and Molecular Characteristics of Locally Advanced and Oligometastatic Renal Cell Carcinoma.
- DIP-like Adenocarcinoma Presenting as a Part-Solid Nodule: A Case Report.